Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial
Sign Up to like & getrecommendations! Published in 2017 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2017.08.016
Abstract: Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator… read more here.
Keywords: anti fibrotic; cirrhosis; study; pri 724 ... See more keywords